VENTURE CAPITAL POST

Geron Corp licensed its cancer compound, the last in its pipeline, to a unit of Johnson & Johnson for up to $935 million, sending its shares up as much as 33 percent in extended trading.

How long patients survive after surgery to remove lung cancer may depend on factors like insurance, income and education, according to a new study.

AstraZeneca's cancer drug pipeline, already on a roll following promising clinical trial results, could get a further boost next week from a European green light for an experimental medicine against ovarian cancer.

The U.S. Food and Drug Administration said on Friday it has approved Japanese pharmaceutical company Eisai's drug Akynzeo to treat nausea and vomiting in patients undergoing chemotherapy for cancer.

U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

AstraZeneca's MedImmune unit has partnered with Immunocore, a private British biotechnology company, to develop a cancer drug that would tap on the body's immune system, Reuters reported.

USD9 million was raised in Series A funding round for ImmunGene Inc.

immatics raises EUR34 million in its latest Series D round financing.